CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Clinical trial NCT03896269 · RECRUITING

Trial details

NCT number: NCT03896269
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Blasts 10-19 Percent of Bone Marrow Nucleated Cells Blasts More Than 5 Percent of Bone Marrow Nucleated Cells High Risk Chronic Myelomonocytic Leukemia Recurrent Chronic Myelomonocytic Leukemia Recurrent High Risk Myelodysplastic Syndrome Refractory Chronic Myelomonocytic Leukemia Refractory High Risk Myelodysplastic Syndrome

Start date: 2019-05-14
Primary completion: 2027-12-31
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.